Adjuvant_chemotherapy_of_high-grade_osteosarcoma_of_the_extremity._Updated_results_of_the_Multi-Institutional_Osteosarcoma_Study._The_Multi-Institutional_Osteosarcoma_Study_(MIOS)_was_designed_to_determine_whether_intensive_multiagent_adjuvant_chemotherapy_improves_the_outcome_of_patients_with_nonmetastatic_high-grade_osteosarcoma_of_the_extremity_as_compared_with_concurrent_controls._After_definitive_surgery_of_the_primary_tumor,_patients_were_randomly_assigned_to_immediate_adjuvant_chemotherapy_or_to_observation_without_adjuvant_treatment._Updated_results_of_this_trial_indicate_that_the_projected_six-year_event-free_survival_for_the_control_group_is_11%_compared_to_61%_for_the_chemotherapy_group_(p_less_than_0.001)._Similar_results_were_observed_in_patients_who_declined_randomization_but_who_were_followed_according_to_the_treatment_arms_of_the_protocol._When_randomized_and_nonrandomized_patients_are_pooled_according_to_assigned_treatment,_a_survival_advantage_favoring_those_patients_treated_with_immediate_adjuvant_chemotherapy_is_apparent._An_analysis_of_prognostic_factors_among_patients_receiving_immediate_adjuvant_chemotherapy_reveals_that_elevation_of_the_serum_lactic_dehydrogenase_at_diagnosis_is_the_factor_most_predictive_of_adverse_outcome._Location_of_the_primary_site_in_the_tibia_confers_a_favorable_prognosis._The_authors_conclude_that_the_natural_history_of_high-grade_osteosarcoma_of_the_extremity_has_not_changed_over_the_past_two_decades._The_administration_of_immediate_adjuvant_chemotherapy_has_a_significant_favorable_impact_on_event-free_survival_and_should_be_recommended_for_all_such_patients.